Vicor Technologies announced that it has selected Dell’s Healthcare and Life Sciences division to serve as its worldwide hardware partner for Vicor’s PD2i Analyzer CA™ (Cardiac Analyzer). Dell will fabricate Victor-labeled laptop computers customized to Vicor’s specifications and packaged for worldwide distribution.
The Vicor PD2i system is a medical device designed to identify risk levels of specific target populations for future pathological events, including congestive heart failure patients’ chances of cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (“DAN”), and trauma victims for imminent death without intervention. The innovative technology is based on Vicor’s propriety nonlinear algorithms and software and has received FDA 510(k) marketing clearance. Vicor is in the process of commercializing the diagnostic system that is non-invasive and produces risk ratings almost immediately upon completion of testing.
Dr. Scott Jenkins, Vice President of Dell, Inc., commented, “Dell Healthcare and Life Sciences is proud to be chosen as Vicor’s worldwide IT solutions provider. Dell is committed to developing and supporting healthcare IT solutions to improve care and delivery.”
David H. Fater, CEO of Vicor Technologies, stated, “We’re thrilled to have Dell as our worldwide IT solutions partner. Dell’s well-established reputation for creating innovative technologies and business solutions, strong internal development capabilities, global reach, and consumer-centric approach make it the perfect worldwide IT solutions partner for Vicor,” Mr. Fater continued, “Given the growing amount of positive feedback we’re receiving from physicians and cardiologists using the PD2i Analyzer™ to enhance diagnosis of those at risk of cardiac death from arrhythmia or pump failure, as well as autonomic neuropathy, we’re extremely optimistic about the prospects for the PD2i Analyzer™ and PD2i CA™ worldwide. These diagnostics have enabled the physicians and cardiologists using them to use existing CPT codes for reimbursement, strengthened their ability to diagnose difficult to identify conditions, and enabled early, sometimes life-saving treatment.”
The PD2i CA™ is only one of several diagnostic devices that Vicor is researching and testing. A device that has unlimited capacities for our veterans returning from duties worldwide is also in clinical trials. The PD2i VS™ (Vital Sign) is being developed through a collaborative effort with the U.S. Army Institute for Surgical Research risk stratifies combat and civilian trauma victims.
More information on Vicor Technologies and its PD2i Systems is available at the Company’s website at www.vicortech.com.
Let us hear your thoughts below: